Document is current
Any future updates will be listed below
-
Authors
Smith, Rebecca G. https://orcid.org/0009-0008-3116-3562
Fu, Yu https://orcid.org/0000-0001-6252-3075
Schiela, Kathleen L.
Dautle, Madison https://orcid.org/0009-0004-7927-3825
Williams, Ryan A. https://orcid.org/0009-0001-5764-5462
Wilson, Hannah M. https://orcid.org/0009-0003-8352-8256
Azadegan, Chloe
Whetstine, Johnathan R.
Dekker, Job https://orcid.org/0000-0001-5631-0698
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA006927)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM154879)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM144131)
W. W. Smith Charitable Trust (C2407)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG003143)
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 13 July 2026
First Online: 20 July 2026
Change Date: 30 July 2026
Change Type: Update
Change Details: In the Funding section of this article the grant number relating to National Institutes of Health Common Fund 4D Nucleome Program given for Job Dekker incorrectly listed ‘HG011536’. The original article has been corrected.
Ethics
Competing interests: J.D. is a member of the scientific advisory board of Arima Genomics, San Diego, CA, USA, and Omega Therapeutic, Cambridge, MA, USA. J.R.W. has served or is serving as a consultant or advisor for Qsonica, Salarius Pharmaceuticals, Daiichi Sankyo, Inc., Vyne Therapeutics, and Lily Asia Ventures. J.R.W. also receives funding for research from Salarius Pharmaceuticals and Oryzon Genomics.
